Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(NY:
CLDI
)
1.560
-0.010 (-0.64%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CLDI
GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 02, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member
July 16, 2024
Via
Investor Brand Network
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
July 16, 2024
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Calidi to Effect Reverse Stock Split
July 05, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
June 27, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
June 11, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
June 10, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
June 03, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
May 31, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
May 24, 2024
Via
ACCESSWIRE
Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV
May 17, 2024
Via
ACCESSWIRE
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
May 14, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
May 01, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
April 23, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
April 19, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
April 16, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
April 09, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
March 15, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
March 11, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
February 12, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
January 08, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
December 13, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
December 12, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
November 20, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results
November 14, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
November 03, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
November 01, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
October 30, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
October 10, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.